1. Home
  2. INTS vs JXG Comparison

INTS vs JXG Comparison

Compare INTS & JXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INTS
  • JXG
  • Stock Information
  • Founded
  • INTS 2012
  • JXG N/A
  • Country
  • INTS United States
  • JXG China
  • Employees
  • INTS N/A
  • JXG N/A
  • Industry
  • INTS Biotechnology: Pharmaceutical Preparations
  • JXG
  • Sector
  • INTS Health Care
  • JXG
  • Exchange
  • INTS Nasdaq
  • JXG Nasdaq
  • Market Cap
  • INTS 12.2M
  • JXG 10.4M
  • IPO Year
  • INTS 2023
  • JXG N/A
  • Fundamental
  • Price
  • INTS $0.31
  • JXG $0.90
  • Analyst Decision
  • INTS Strong Buy
  • JXG
  • Analyst Count
  • INTS 4
  • JXG 0
  • Target Price
  • INTS $4.50
  • JXG N/A
  • AVG Volume (30 Days)
  • INTS 5.0M
  • JXG 1.9M
  • Earning Date
  • INTS 11-12-2025
  • JXG 05-15-2025
  • Dividend Yield
  • INTS N/A
  • JXG N/A
  • EPS Growth
  • INTS N/A
  • JXG N/A
  • EPS
  • INTS N/A
  • JXG 0.86
  • Revenue
  • INTS N/A
  • JXG $49,840,288.00
  • Revenue This Year
  • INTS N/A
  • JXG N/A
  • Revenue Next Year
  • INTS N/A
  • JXG N/A
  • P/E Ratio
  • INTS N/A
  • JXG $1.04
  • Revenue Growth
  • INTS N/A
  • JXG 56.53
  • 52 Week Low
  • INTS $0.19
  • JXG $0.55
  • 52 Week High
  • INTS $3.75
  • JXG $7.72
  • Technical
  • Relative Strength Index (RSI)
  • INTS 64.31
  • JXG 48.04
  • Support Level
  • INTS $0.27
  • JXG $0.84
  • Resistance Level
  • INTS $0.30
  • JXG $1.02
  • Average True Range (ATR)
  • INTS 0.03
  • JXG 0.11
  • MACD
  • INTS 0.01
  • JXG 0.01
  • Stochastic Oscillator
  • INTS 60.25
  • JXG 48.63

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

About JXG JX Luxventure Limited Common Stock

JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products.

Share on Social Networks: